Abstract
Rationale Elderly ILD patients are more likely to be frail and to have comorbidities that complicate their care. We investigated the efficacy and safety of nintedanib in elderly patients with progressive fibrosing (PF-) ILDs other than idiopathic pulmonary fibrosis (IPF) in the INBUILD trial ([Abb. 1]).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
